CopyFind
Mifistar 25 Tablet
medicine 📍 IN

Mifistar 25 Tablet

390,00 ₹

Analogs of Mifistar 25 Tablet

Find cheaper analogs and generic equivalents for Mifistar 25 Tablet.

Ingredients

Principe actif : Mifepristone


Aperçu du produit

About Mifistar 25 Tablet

Mifistar 25 Tablet is a medication containing the active ingredient Mifepristone, classified as Progestin Antagonist. Mifepristone, also known by its developmental code name RU-486, is a drug typically used in combination with misoprostol to bring about a medical abortion during pregnancy. This combination is 97% effective during the first 63 days of pregnancy, and is effective in the second trimester as well.

Key Benefits & Uses

  • Used for: 1 INDICATIONS AND USAGE KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in.
  • Use only as directed on the product label or by a healthcare professional.
  • Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Mifepristone, the active ingredient in Mifistar 25 Tablet, belongs to the Progestin Antagonist class. 1 INDICATIONS AND USAGE KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Mifistar 25 Tablet. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Mifistar 25 Tablet for extended periods without medical advice.

Find in Pharmacies

Compare local prices and distance for Mifistar 25 Tablet.

Visitor ratings

Help others by rating how useful this product page is.

No ratings yet — be the first.